Arbekacin, an aminoglycoside antibiotic, is an important drug because it shows a potent efficacy against methicillin-resistant Staphylococcus aureus. However, resistance to arbekacin, which is caused mainly by the bifunctional aminoglycoside-modifying enzyme, has been observed, becoming a serious problem in medical practice. To create new arbekacin derivatives active against resistant bacteria, we modified the C-4″ and 6″ positions of its 3-aminosugar portion. Regioselective amination of the 6″-position gave 6″-amino-6″-deoxyarbekacin (1), and it was converted to a variety of 6″-N-alkanoyl derivatives (6a − z). Furthermore, regioselective modifications of the 4″-hydroxyl group were performed to give 4″-deoxy-4″-epiaminoarbekacin (2) and its 4″-N-alkanoyl derivatives (12 and 13). Their antibacterial activity against S. aureus, including arbekacin-resistant bacteria, was evaluated. It was observed that 6″-amino-6″-N-[(S)-4-amino-2-hydroxybutyryl]-6″-deoxyarbekacin (6o) showed excellent antibacterial activity, even better than arbekacin.
INTRODUCTION
Aminoglycoside antibiotics have been widely used in the treatment of serious infections caused by Gram-positive and/or Gram-negative bacteria. They interfere with bacterial protein synthesis by binding to the A-site decoding region of 16S rRNA in the 30S ribosomal subunit. [1] [2] [3] [4] [5] Arbekacin (ABK), which was synthesized from dibekacin by the attachment of the (S)-4-amino-2-hydoxybutyryl (AHB) 6 residue at the N-1 position, is efficacious for methicillin-resistant Staphylococcus aureus (MRSA), and is used for the treatment of infected patients. 7, 8 However, the emergence of ABK-resistant MRSA, caused by bifunctional aminoglycoside-modifying enzyme AAC (6′)-APH (2″), has been observed, and causes a serious problem. [9] [10] [11] Moreover, the appearance of aminoglycoside-resistant Pseudomonas aeruginosa and Acinetobacter has recently been reported. 12 Therefore, development of a new type of ABK derivative active against resistant bacteria is urgently required to fight against the diseases caused by the pathogens.
Deoxygenation, epimerization and/or deoxyamination have frequently strengthened the antibacterial activity of aminoglycoside antibiotics. [13] [14] [15] For example, 5-deoxy-5-epi substitution 16 and 5, 4″-diepimerization 17 enhanced the antibacterial activity of ABK, including the activity against resistant bacteria. Also, it is well known that the introduction of the amino acid side-chain to the 1-amino group brings an improvement in antimicrobial activity. [18] [19] [20] [21] Furthermore, their combined modification is also thought to be an attractive approach. 6″-Amino-6″-deoxy-arbekacin (1) 22 and 4″-deoxy-4″-epiamino-arbekacin (2), 17 which introduced an amino group in the 4″ or 6″-position of its 3-aminosugar portion, were reported to preserve the antibacterial activity. In addition, the specific mechanism of the binding affinity of the hydroxyl groups at these positions to the bacterial 16S rRNA has not been determined. These phenomena suggest that there is great potential for improvement of activity by chemical modification in this area. Therefore, we focused on the 3-aminosugar portion bearing a novel amino group, to create new ABK derivatives active against resistant bacteria, and planned a structure-activity relationship study on the N-acyl derivatives of the novel amino group.
In this paper, we describe the synthesis of 4″-alkanoylamino-4″-epi or 6″-alkanoylamino derivatives of ABK by regioselective amination and their antibacterial activities against S. aureus including ABK-resistant MRSA.
RESULTS AND DISCUSSION
Synthesis and antibacterial activity of 6″-alkanoylamino derivatives of ABK Synthesis of 1 and its 6″-N-alkanoyl derivatives is shown in Scheme 1.
Penta-N-Boc-6″-O-triisopropylbenzenesulfonyl ABK (3) was obtained from penta-N-Boc ABK 17 via selective sulfonylation of the 6″-hydroxyl group with 2, 4, 6-triisopropylbenzenesulfonyl chloride (TIBS-Cl) at room temperature with 90% yield. In the 1 H NMR spectrum of 3 in dimethyl sulfoxide (DMSO)-d 6 , the H-6″ signals of penta-N-Boc ABK at 3.51 and 3.58 p.p.m. shifted to 4.11 and 4.28 p.p.m., respectively, confirming the selective sulfonylation of 6″-hydroxyl group in 3 (refer to experimental section). Introduction of the leaving groups by other reagents such as p-toluenesulfonyl chloride, methanesulfonyl chloride or I 2 with triphenylphosphine resulted in a decrease in regioselectivity. Treatment of 3 with NaN 3 followed by reduction of the resulting azide group by the Staudinger reaction 23 produced 6″-amine 4 in a high yield. Deprotection of 4 with aqueous trifluoroacetic acid provided 6″-amino-6″-deoxyarbekacin (1) . Although the synthesis of 1 was described for a previous procedure, 22 we have established a more convenient method. On the other hand, N-alkanoylation of 4 with various carboxylic acids was effectively attained by using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4methylmorpholinium chloride (DMT-MM) 24 or the activated ester method 25 to give 5a − z with 41 − 95% yield. Removal of Boc groups afforded a variety of 6″-alkanoylamino-6″-deoxy derivatives (6a − z) of ABK (refer to Supplementary Information). The position of newly introduced acyl groups in 6a − z was confirmed by HMBC correlations between the amide carbonyl and the hydrogens at C-6″. The structures of 5a − z and 6a − z are shown in Figure 1 .
The antibacterial activities of 6″-amino-6″-deoxyarbekacin (1) and its 6″-N-alkanoyl derivatives 6a − z are shown in Table 1 .
The derivatives (6a − j, w − y) containing the aromatic or aliphatic rings in the side-chains were less active than ABK. However, 6x and 6y, possessing the terminal amino group, showed moderate antibacterial activity, and this result suggested that the terminal amino group in the side-chain is important for the activity. In contrast, the derivatives (6k − v) containing the functionalized linear chain were likely to display a relatively potent antibacterial activity. In particular, compounds 6n and 6o, with the (S)-3-amino-2-hydroxypropionyl and (S)-AHB residue, respectively, showed highly efficacious antibacterial activity against ABK-resistant MRSA MS16526 (the resistant mechanism is a bifunctional enzyme AAC (6′)-APH (2″)). This result indicated that the antibacterial activity is enhanced by the addition of the amino side-chain even in the case of the novel amino group at the C-6″ position. Improvement of antibacterial activity against ABK-resistant MRSA is suspected to be a likely result of the inhibition of bifunctional enzyme AAC (6′)-APH (2″). In the AHB side-chain, a comparison between 6o and 6p indicated that the S-configuration is SAR of 4″ or 6″-derivatives of arbekacin K Sasaki et al preferable over the R-configuration. When the carbon-chain becomes longer than that of AHB, the activity tended to decrease, and a similar phenomenon was reported in the case of 1-N-alkanoyl derivatives of ABK. 26 Compound 6s demonstrated that the replacement of the hydroxyl group by an amino group at the alpha position of the linear side-chain displays excellent activity. Further, it was indicated in the compound 6t that the replacement of the terminal amino group by the guanidine group shows similar effects in terms of antimicrobial activity. Interestingly, although 6n and 6v have the same functional groups in the side-chain, 6n was more active than 6v because of the difference in the position of the two functional groups. These results indicated the importance of the presence and location of the basic functional groups for antibacterial activity. Moreover, we evaluated the antibacterial activity of 6o against Escherichia coli and P. aeruginosa as Gram-negative bacteria and Enterococcus faecalis as Gram-positive bacteria ( Table 2) . On the whole, 6o was equal or more active than ABK against these bacteria, in particular, it exhibited prominent activity against P. aeruginosa.
Synthesis and antibacterial activity of 4″-alkanoylamino-4″-epi derivatives of ABK
We expected that the introduction of the AHB residue into the 4″-epiamino group would potentiate the antibacterial activity, as inferred from the results of the SAR study on 6″-N-alkanoyl derivatives. Synthesis of 4″-deoxy-4″-epiaminoarbekacin (2) and its 4″-N-alkanoyl derivatives is shown in Scheme 2.
The reaction of 2″, 2‴-di-O-acetyl-3, 2′, 6′, 3″, 4‴-penta-N-Boc-6″-O-trityl ABK 17 (7) with methanesulfonyl chloride (MsCl) produced the 4″-O-mesyl derivative 8 in a high yield. Treatment of 8 with NaN 3 followed by removal of the acetyl groups and the Staudinger reaction 23 of the azide group gave the 4″-epiamine 10. Deprotection of Boc and Tr groups under acidic conditions provided 2. On the other hand, N-alkanoylation of 10 with (S)-2-benzyloxy-4-benzyloxycarbonylaminobutyric acid gave 11 in 86% yield. Removal of the Boc groups of 11 led to 12, and the deprotection of the Bn and Cbz groups provided the bis-AHB derivative 13.
The antibacterial activities of 4″-deoxy-4″-epiaminoarbekacin (2) and its 4″-N-alkanoyl derivatives (12 and 13) against S. aureus are shown in Table 3 . The 4″-deoxy-4″-epiamino derivative 2 showed moderate activity against Methicillin-sensitive S. aureus, although its activity against MRSA strains was remarkably lower than that of ABK as reported. 17 On the other hand, compound 12, which introduced the N,O-protected AHB residue into the axial amino group at the C-4″ position was not active. In contrast, the bis-AHB derivative 13 showed more potent antibacterial activity than that of 2 or 12. This suggested that the addition of the amino side-chain to the novel axial amino group at the C-4″ position also enhances the antibacterial activity.
CONCLUSIONS
We synthesized the 4″ or 6″-alkanoylamino derivatives of ABK via the regioselective sulfonylation of the hydroxyl groups at the corresponding positions. 6″-Alkanoylamino derivatives, which introduced the (S)-3-amino-2-hydroxypropionyl (6n) or AHB (6o) residue, showed potent antibacterial activity against S. aureus including ABK-resistant MRSA, although the 4″-alkanoylamino-4″-epi derivative 13 was less active than ABK. Furthermore, 6o was more active than ABK against Gram-negative bacteria such as E. coli and P. aeruginosa. This study can provide a basis for development of novel aminoglycoside antibiotics for clinically relevant bacteria that are recalcitrant to antibiotic treatment.
EXPERIMENTAL PROCEDURE General information
NMR spectra were recorded on a Bruker DPX 400 or AVANCE 500 spectrometer (Bruker, Billarica, MA, USA). Chemical shifts were measured downfield from tetramethylsilane as an internal standard. Mass spectra were acquired on a Thermo Scientific LTQ XL spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) (ESI) or LTQ Orbitrap mass spectrometer (HRMS 6″-Amino-6″-deoxyarbekacin (1) . A solution of 4 (650 mg, 0.6 mmol) in TFA − H 2 O (9:1, 13 ml) was kept at 0°C for 2 h. Concentration gave a residue that was purified by resin column chromatography to provide 1 22 (358 mg, 94% as a carbonate) as a colorless solid.
. To a solution of 4 (50 − 300 mg, 0.05 − 0.29 mmol) in MeOH − THF − H 2 O (15:7.5:1, 17.5 ml), a variety of carboxylic acids (1.5 eq) and DMT-MM (2 eq) were added, and the mixture was stirred at room temperature for 1 day.
Concentration gave a residue that was extracted with CHCl 3 . The organic solution was washed with saturated aqueous NaHCO 3 and water, dried over MgSO 4 and concentrated. The resulting residue was purified by silica gel column chromatography to provide 5 (41 − 90%) as a colorless solid. Amidation by activated ester method (5m − r,w). To a solution of 4 (1.0 g, 0.95 mmol) in THF (20 ml), Et 3 N (0.33 ml, 2.4 mmol) and N-hydroxysuccinimide ester of the corresponding amino acid (5.71 mmol) were added, and the mixture was stirred at room temperature for 19 h. The reaction mixture was quenched with 1M aqueous NH 3 , and the mixture was evaporated. The residue was extracted with CHCl 3 and the organic solution was washed with saturated aqueous NaHCO 3 and water, dried over MgSO 4 and concentrated in vacuo. The residue was purified by silica gel column chromatography to provide 5 (92 − 95%) as a colorless solid.
6″-N-Alkanoylamino-6″-deoxyarbekacin (6a − z). A solution of 5 (31 − 720 mg) in TFA − H 2 O (9:1, 20 v/w) was kept at 0°C for 2 h. The solution was concentrated in vacuo, and then the residue was purified by resin column chromatography to provide 6 (91 − 97% as a carbonate) as a colorless solid. Compound 6o. 1 (8) . To a solution of 7 17 (11.0 g, 7.97 mmol) in pyridine (220 ml) methanesulfonyl chloride (4.9 ml, 63.8 mmol) was added, and the mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with MeOH (22 ml) and was evaporated. The resulting residue was extracted with AcOEt, and the organic solution was washed with saturated aqueous NH 4 Cl and water, dried over MgSO 4 and concentrated. The residue was purified by silica gel column chromatography to provide 8 (11.0 g, 95%) as a colorless solid. ESI-MS calculated for C 71 H 104 N 6 NaO 24 S: 1479.67; found: 1479.60 (M+Na) + .
2″,2‴-Di-O-acetyl-3, 2′, 6′, 3″, 4‴-penta-N-tert-Boc-4″-deoxy-4″-epiazide-6″-Otrityl-arbekacin (9) . To a solution of 8 (12.0 g, 8.23 mmol) in DMF (360 ml) NaN 3 (13.4 g, 206 mmol) was added, and the mixture was stirred at 100°C for 1 day. Concentration gave a residue that was extracted with AcOEt. The organic layer was washed with water, dried over MgSO 4 and concentrated. The resulting residue was purified by silica gel column chromatography to provide 9 (2.0 g, 17%) as a colorless solid. In previous study, 17 the yield of 9 was 58% from 7. Aiming at improvement of the yield, we used 4″-O-Ms derivative 8 as a starting material of 9, however, the result was a low yield because of elimination products (2″,2‴-Di-O-acetyl-3, 2′, 6′, 3″, 4‴-penta-N-tert-Boc-4″-deoxy-4″,5″ene -6″-O-tritylarbekacin and 2″,2‴-Di-O-acetyl-3, 2′, 6′, 3″, 4‴-penta-N-tert-Boc-4″-deoxy-3″,4″-ene -6″-O-tritylarbekacin). ESI-MS calculated for C 70 H 101 N 9 NaO 21 : 1426.70; found: 1426.82 (M+Na) + .
3, 2′, 6′, 3″, 4‴-Penta-N-tert-Boc-4″-deoxy-4″-epiamino-6″-O-tritylarbekacin (10) . A solution of 9 (2.0 g, 1.42 mmol) in MeOH − aqueous concentrated NH 3 (2:1, 90 ml) was stirred at room temperature for 2 h. Concentration gave a 2″, 2‴-dihydroxyl derivative 9a (1.9 g) as a solid. ESI-MS calculated for C 66 H 97 N 9 NaO 19 : 1342.68; found: 1342.78 (M+Na) + . To a solution of 9a (1.9 g, 1.44 mmol) in THF − H 2 O (4:1, 30 ml) PPh 3 (1.13 g, 4.31 mmol) was added, and the mixture was stirred at 50°C for 20 h. After concentration, the resulting residue was dissolved in pyridine (119 ml). To the solution concentrated aqueous NH 3 (90 ml) was added, and the mixture was stirred at room temperature for 3 days. The reaction mixture was concentrated, and then the residue was purified by silica gel column chromatography to provide 10 (900 mg, 49% from 9) as a colorless solid. ESI-MS calculated for C 66 H 99 N 7 NaO 19 : 1316.69; found: 1316.82 (M+Na) + .
